WINT
Windtree Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Nov. 18, 9:08 AM
    • Nasdaq notifies Windtree Therapeutics (NASDAQ:WINT) that it no longer complies with listing requirements due to its failure to maintain a minimum stockholders equity of $2.5M. It has 180 calendar days to address the issue.
    | Fri, Nov. 18, 9:08 AM | 1 Comment
  • Wed, Aug. 10, 4:23 PM
    • Windtree Therapeutics (NASDAQ:WINT): Q2 EPS of -$1.29 beats by $0.35.
    • Revenue of $0.11M (+37.5% Y/Y) beats by $0.07M.
    • Press Release
    | Wed, Aug. 10, 4:23 PM
  • Thu, May 12, 7:16 AM
    • Windtree Therapeutics (NASDAQ:WINT): Q1 EPS of -$1.70 misses by $0.12.
    • Revenue of $0.075M (-60.7% Y/Y).
    | Thu, May 12, 7:16 AM | 1 Comment
  • Mon, Apr. 11, 12:47 PM
    | Mon, Apr. 11, 12:47 PM
  • Thu, Mar. 24, 8:00 AM
    • Discovery Laboratories (DSCO) Q4 results: Revenues: $0.7M (-41.7%); R&D Expense: $8.2M (+5.1%); SG&A: $2.2M (-40.5%); Operating Loss: ($9.8M) (+12.5%); Net Loss: ($10.1M) (+4.7%); Loss Per Share: ($1.26) (+40.0%).
    • FY2015 results: Revenues: $1M (-64.3%); R&D Expense: $28.9M (+8.2%); SG&A: $11M (-34.1%); Operating Loss: ($39.8M) (+8.1%); Net Loss: ($55.2M) (-25.2%); Loss Per share: ($7.98) (-1.8%); Quick Assets: $38.7M (-13.4%).
    • No guidance given.
    | Thu, Mar. 24, 8:00 AM
  • Thu, Mar. 24, 7:05 AM
    • Discovery Laboratories (NASDAQ:DSCO): Q4 EPS of -$1.26 misses by $0.56.
    • Revenue of $0.66M (-44.1% Y/Y) beats by $0.59M.
    | Thu, Mar. 24, 7:05 AM
  • Dec. 29, 2015, 5:11 PM
    • Discovery Laboratories (NASDAQ:DSCO) commences a Phase 2b clinical trial evaluating AEROSURF in premature infants, 26 to 32 weeks gestational age, receiving non-invasive nasal continuous airway pressure (nCPAP) for respiratory distress syndrome (RDS). The aim of the study is to assess premature infants receiving aerosolized KL4 surfactant (including repeat doses, if required) compared to nCPAP alone. If successful, the trial will inform the design of a Phase 3 trial.
    • Currently, premature infants with severe RDS receive surfactant therapy via invasive endotracheal intubation so aerosolized administration offers significant advantages such as the avoidance of serious complications. Infants with less severe RDS are typically treated with nCPAP, but many respond poorly, thereby delaying surfactant therapy.
    • AEROSURF is an investigational drug/device product that combines the company's proprietary KL4 surfactant and its aerosolization technologies. According to the company, as many as 150K premature infants each year in the U.S. could benefit from surfactant therapy.
    | Dec. 29, 2015, 5:11 PM | 1 Comment
  • Nov. 5, 2015, 5:50 PM
    • Discovery Laboratories (NASDAQ:DSCO): Q3 EPS of -$0.20 may not be comparable to consensus of -$0.08.
    • Revenue of $0.07M (-86.8% Y/Y) misses by $0.22M.
    | Nov. 5, 2015, 5:50 PM
  • Aug. 10, 2015, 4:48 PM
    • Discovery Laboratories (NASDAQ:DSCO): Q2 EPS of -$0.13 in-line.
    • Revenue of $0.08M (-92.7% Y/Y) misses by $0.19M.
    | Aug. 10, 2015, 4:48 PM
  • May 14, 2015, 12:45 PM
    | May 14, 2015, 12:45 PM
  • May 14, 2015, 9:16 AM
    | May 14, 2015, 9:16 AM | 2 Comments
  • May 13, 2015, 12:45 PM
    | May 13, 2015, 12:45 PM | 1 Comment
  • May 7, 2015, 5:34 PM
    • Discovery Laboratories (NASDAQ:DSCO): Q1 EPS of -$0.14 misses by $0.03.
    • Revenue of $0.2M
    | May 7, 2015, 5:34 PM
  • Apr. 17, 2015, 12:45 PM
    | Apr. 17, 2015, 12:45 PM
  • Apr. 17, 2015, 11:21 AM
    • Discovery Labs (DSCO -16.7%) completes the enrollment of 48 premature infants 29 - 34 week gestational age with respiratory distress syndrome (RDS) in a Phase 2a study evaluating the administration of a single dose of AEROSURF, the company's investigational drug/device product that combines its synthetic KL4 surfactant with its proprietary capillary aerosol generator. The multi-center open-label trial will assess the safety and tolerability of a single dose of KL4 surfactant in premature infants who are receiving nasal continuous positive airway pressure (nCAP) for RDS, compared to infants receiving nCPAP alone. The company will report the results and hold an investor conference in three to four weeks.
    • AEROSURF is designed to replace SURFAXIN (lucinactant) Intratracheal Suspension, approved in 2012, which is administered by endotracheal intubation supported by mechanical ventilation, a frequent cause of complications. The company is currently exploring the potential for another firm taking over the commercialization of SURFAXIN via some form of strategic alliance, but if one cannot be consummated, then it will cease marketing the product.
    | Apr. 17, 2015, 11:21 AM | 5 Comments
  • Apr. 17, 2015, 9:21 AM
    | Apr. 17, 2015, 9:21 AM